-$0.13 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter

Equities analysts predict that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will announce earnings of ($0.13) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.10). Catalyst Pharmaceuticals posted earnings of ($0.06) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 116.7%. The firm is expected to issue its next quarterly earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.24) per share for the current fiscal year, with EPS estimates ranging from ($0.40) to ($0.13). For the next year, analysts anticipate that the business will post earnings of $0.34 per share, with EPS estimates ranging from $0.12 to $0.86. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $0.50 million for the quarter.



Several research firms have weighed in on CPRX. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. ValuEngine upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, March 25th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $10.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $6.55.

NASDAQ CPRX traded up $0.16 during trading hours on Monday, hitting $5.55. 39,493 shares of the company’s stock traded hands, compared to its average volume of 3,136,853. Catalyst Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $5.68. The stock has a market cap of $553.77 million, a PE ratio of -16.76 and a beta of 2.43.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Broadfin Capital LLC lifted its holdings in Catalyst Pharmaceuticals by 22.0% during the 4th quarter. Broadfin Capital LLC now owns 6,268,298 shares of the biopharmaceutical company’s stock worth $12,035,000 after buying an additional 1,132,034 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 11.5% during the fourth quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock worth $13,384,000 after buying an additional 719,093 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $990,000. Vanguard Group Inc grew its holdings in shares of Catalyst Pharmaceuticals by 4.3% during the third quarter. Vanguard Group Inc now owns 4,458,151 shares of the biopharmaceutical company’s stock worth $16,852,000 after buying an additional 185,017 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 4.3% during the third quarter. Vanguard Group Inc. now owns 4,458,151 shares of the biopharmaceutical company’s stock worth $16,852,000 after buying an additional 185,017 shares in the last quarter. Hedge funds and other institutional investors own 47.83% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Article: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.